and 5 INTERFANT-99 Collaborative Study Group MLL rearranged acute lymphoblastic leukemia (MLL) is an aggressive type of acute lymphoblastic leukemia (ALL), diagnosed predominantly in infants (o1 years of age). Since current chemotherapy fails in 450% of patients with MLL, new therapeutic strategies are desperately needed. For this, understanding the biological features characterizing MLL is necessary. Analysis of gene expression profiles revealed that the expression of the tumor suppressor gene FHIT is reduced in children with MLL rearranged ALL as compared to ALL patients carrying germ line MLL. This finding was confirmed by quantitative real-time PCR. In 100% of the infant MLL cases tested, methylation of the FHIT 5 0 CpG region was observed, resulting in strongly reduced mRNA and protein expression. In contrast, FHIT methylation in infant and non-infant ALL patients carrying germ line MLL was found in only B60% (Pp0.004). FHIT expression was restored upon exposing leukemic cells to the demethylating agent decitabine, which induced apoptosis. Likewise and more specifically, leukemic cell death was induced by transfecting MLL rearranged leukemic cells with expression vectors encoding wild-type FHIT, confirming tumor suppressor activity of this gene. These observations imply that suppression of FHIT may be required for the development of MLL, and provide new insights into leukemogenesis and therapeutic possibilities for MLL.
Introduction
In contrast to acute lymphoblastic leukemia (ALL) diagnosed in children ranging from 1 to 9 years of age, ALL in infants (o1 year of age) is associated with an exceedingly poor treatment outcome, 1,2 mainly due to cellular drug resistance. [3] [4] [5] Furthermore, ALL at infancy is characterized by a high incidence of balanced chromosomal translocations involving the mixed lineage leukemia (MLL, ALL-1, or HRX) gene, which occur in approximately 75% of the cases. [2] [3] [4] The most commonly found translocations involving MLL in infant ALL include t(4;11)(p21;q23) (B60%), t(11;19)(q23;p13.3) (B20%) and, t(9;11)(p22;q23) (B5%). Infants diagnosed with MLL rearranged ALL have a poor prognosis (with an event-free survival of B35%), 1,2 whereas infant ALL patients carrying germ line MLL seem to have a far better outcome. 6, 7 Recently, we demonstrated that MLL gene rearranged ALL (designated MLL) displays a gene expression profile that is clearly distinguishable from both ALL and acute myeloid leukemia (AML) bearing germ line MLL genes. 8 Taken together these characteristics indicate that MLL is a distinct biological entity that responds poorly to conventional ALL-directed therapy. Therefore, in order to improve the prognosis of this disease, new therapeutic strategies are urgently needed. For this, understanding both the biology and etiology of this disease is crucial. Important aspects of the biology of MLL like high-level expression of certain HOX genes 8, 9 and of Fms-like tyrosine kinase 3 (FLT3), [8] [9] [10] are now emerging and, as shown here, continue to emerge from gene expression analysis.
Gene expression profiling revealed that numerous genes are differentially expressed between ALL patients with and without MLL gene rearrangements, including FHIT of which the expression appears to be reduced in MLL (Figure 1a ). The FHIT gene is located on chromosome 3p14.2 encompassing the most active common fragile site in the human genome, that is, the FRA3B locus. 11 The encoded protein FHIT is a member of the histidine triad protein (HIT) family and appears to be the human orthologue of the yeast Scizosaccharomyces pombe protein Aph1 as it exhibits diadenosine triphosphate hydrolase activity. 11, 12 Restoring FHIT expression in cancer cells that lack FHIT expression has been shown to induce apoptosis and suppresses tumorigenicity. 13, 14 Likewise, exogenous FHIT expression in FHIT negative human breast cancer cell lines enforces cells to undergo apoptosis. 15 Furthermore, treating heterozygous Fhit knockout mice with adenoviral constructs encoding human FHIT, inhibits tumor development in the fore stomach upon exposure to the carcinogen N-nitrosomethylbenzylamine. 16 Based on these and other studies, FHIT is hypothesized to be a tumor suppressor gene. Interestingly, FHIT is aberrantly expressed in a wide variety of human cancers, 17 but data on FHIT expression specifically in childhood acute leukemias are limited. In both cervical 18, 19 and gastric cancer, 20 abnormal FHIT expression appeared to be a prognostic factor for an adverse outcome. However, this has not been confirmed in human adult leukemias. 21, 22 In solid tumors, aberrant or absent expression of FHIT most often is due to loss of heterozygosity (LOH) or homozygous deletions, and less frequently to 5 0 CpG island methylation. Recently, however, Zheng et al. (2004) demonstrated that inactivated FHIT as a consequence of 5 0 CpG island hypermethylation can be found in childhood ALL, especially in hyperdiploid and translocation-negative subtypes. 23 Here we report that in a large cohort of MLL rearranged infant ALL cases silencing of FHIT by 5 0 CpG island hypermethylation was observed in 100% of the cases. Furthermore, we show that FHIT silencing could be reversed by exposing cells to the demethylating agent decitabine, which was accompanied by the induction of leukemic cell death. Finally, we demonstrate that transfecting MLL cells lacking endogenous FHIT expression with expression vectors encoding wild-type FHIT induced apoptosis and restored the tumor suppressor activity of this gene.
Patients, materials and methods

Patient samples
Primary bone marrow and/or peripheral blood samples from untreated infants (o1 year of age) diagnosed with ALL were collected at the Erasmus MC/Sophia Children's Hospital and other hospitals participating in the INTERFANT-99 treatment protocol. Samples from ALL patients older than 1 year of age were obtained from the German COALL study. The presence of MLL gene rearrangements was assessed by RT-PCR and FISH analysis. This and other patient characteristics were collected by the involved study centers. Within 24 h after sampling, mononuclear cells were isolated by density gradient centrifugation using Lymphoprep (density 1.077 g/ml; Nycomed Pharma, Oslo, Norway), centrifuged at 480 g for 15 min at room temperature. The collected mononuclear cells were washed twice and kept in culture medium consisting of RPMI 1640 medium (Dutch modification without L-glutamine; Invitrogen life technologies, Breda, The Netherlands), 20% fetal calf serum (FCS; Integro, Zaandam, the Netherlands), 2 mM L-glutamine (Invitrogen) 5 mg/ ml insulin, 5 mg/ml transferrin, 5 ng/ml sodium selenite (ITS media supplement; Sigma, St Louis, MO, USA), 100 IU/ml penicillin, 100 mg/ml streptomycin, 0.125 mg/ml fungizone and 0.2 mg/ml gentamycin (Invitrogen). Contaminating nonleukemic cells were removed by immunomagnetic beads as described by Kaspers et al. (1994) . 24 All samples contained 490% leukemic cells, determined morphologically on May-Grü nwald-Giemsa (Merck, Darmstadt, Germany) stained cytospins. For RNA and DNA isolation, a minimum of 5 Â 10 6 cells were lysed in TRIzol reagent (Invitrogen) and stored at À801C until extraction.
Cell lines
All human leukemia cell lines used in this study were maintained in RPMI 1640 with L-Alanyl-L-Glutamine (Invitrogen) supplemented with 10% FCS (Integro), 100 IU/ml penicillin, 100 mg/ml streptomycin and 0.125 mg/ml fungizone (Invitrogen) and grown as suspension cultures at 371C in humidified air containing 5% CO 2 . Both RS4;11 and SEMK2-M1 are B lineage acute lymphoblastic leukemia cell lines carrying translocation t(4;11). MV4-11 is a myelomonocytic leukemia cell line also bearing translocation t(4;11). Jurkat, Molt-4 and CCRF-CEM all are T-ALL cell lines and HL60 is an acute promyelocytic leukemia line. The cell lines REH and TOM-1 are TEL-AML1 and Philadelphia chromosome positive acute lymphocytic leukemias, respectively, and K563 is a chronic myelogenous leukemia (CML) cell line.
RNA and DNA extraction
Both total RNA and genomic DNA were extracted from a minimum of 5 Â 10 6 leukemic cells using TRIzol reagent (Invitrogen), according to the manufacturer's instructions, with minor modifications. 25 The integrity of the extracted RNA was assessed on 1% agarose gels.
Quantitative real-time PCR (TaqMan
&
)
Extracted RNA was reverse transcribed and the obtained cDNA was used to quantify FHIT mRNA expression relative to the endogenous housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), using quantitative real-time PCR (TaqMan & ) as described previously. 25 Primer and probe sequences used to amplify and detect FHIT and GAPDH expression are listed in Table 1a .
FHIT 5
0 CpG methylation analysis by methylationspecific PCR Exposing DNA to bisulfite converts unmethylated cytosine into uracil bases. Methylated cytosine bases, however are protected from this modification. Therefore, after bisulfite modification, the nucleotide sequence of methylated DNA differs from that of unmethylated DNA. Using primers specific for the predicted sequence of bisulfite treated methylated DNA, allows the amplification of PCR products only when methylated DNA was present before bisulfite exposure. Similarly, primers specific for bisulfite treated unmethylated DNA can be designed.
For bisulfite modification, 5 mg of genomic DNA was denatured in 0.2 M NaOH for 15 min at 371C. Accordingly, 200 ml of a 100 mM hydroquinone, 5 M sodium bisulfite (Sigma) and 0.35 M NaOH (Merck) solution (pH 5) was added per mg of DNA, following a 4 h incubation at 501C in the dark. Bisulfitetreated DNA was subsequently purified using Wizard DNA purification resin (Promega) followed by ethanol precipitation.
Methylation-specific PCR (MSP), using primer sequences specific for either methylated or unmethylated FHIT after bisulfite treatment, was performed essentially as described by Zö chbauer-Mü ller et al. 26 Briefly, MSP was performed in a total reaction volume of 50 ml containing PCR buffer (Qiagen Inc., Valencia, CA, USA), 10 ml Q-solution (Qiagen), 0.4 mM of each dNTP (Amersham Pharmacia Biotech), 3 and 5 mM MgCl 2 for the methylated FHIT and unmethylated FHIT PCR, respectively, 0.6 mM forward and reverse primer, 33 1 U of HotStarTaq (Qiagen) and B100 ng bisulfite treated DNA as a template. Amplification was performed using a touchdown PCR with the annealing temperature decreasing from 71 to 641C over 14 cycles of annealing for 1 min and denaturation for 15 s at 951C, followed by 30 cycles of 951C for 15 s and 641C for 1 min. Amplified PCR products were analyzed on 3% agarose gels.
Methylation of HL60 DNA
Since the human AML cell line HL60 shows significant FHIT protein expression, bisulfite-treated HL60 DNA was used as positive control for the unmethylated FHIT MSP. To generate a positive control for the methylated FHIT MSP, HL60 DNA was enzymatically methylated using the CpG methylase M.Sss I. The methylation reaction was performed in a total volume of 100 ml containing NEBuffer 2, 0.16 mM S-adenosylmethionine, 10 U of M.Sss I methylase (New England BioLabs, Beverly, MA, USA) and 10 mg HL60 DNA, incubated at 371C for 3 h, followed by a 20 min incubation at 651C to inactivate the enzyme. Accordingly, the methylated HL60 DNA was bisulfite modified as described above.
5-aza-2 0 -deoxycytidine (decitabine) treatment of SEMK2 cells
To study the effects of demethylation on FHIT protein expression, SEMK2-M1 cells were maintained in culture medium both in the absence and presence of 1 mM of the demethylating drug 5-aza-2 0 -deoxycytidine (decitabine) (Sigma) for 7 days. The decitabine containing culture medium was refreshed daily. Every 24 h, cell viability was assessed by Annexin V staining determined by flow cytometry using a FACSCalibur (Becton Dickinson). Sampled cells were washed twice in phosphate-buffered saline (PBS), and spun down cell pellets were stored at À801C until protein extraction.
Ectopic FHIT expression in RS4;11 cells
The entire wild-type FHIT coding sequence was amplified using primers containing 5 0 extensions encoding a BamHI (forward primer) or a BglII (reverse primer) restriction sites (Table 1b) . Accordingly, this wild-type FHIT transcript was cloned into the BamHI/BglII site of the eukaryotic expression vector pSG5 (Stratagene, La Jolla, CA, USA).
RS4;11 cells (1 Â 10 7 ) were transfected by electroporation in 400 ml RPMI 1640 with L-Alanyl-L-Glutamine (Invitrogen) containing 4 mg of either the pSG5-FHIT construct or empty vector (mock transfection), in 4 mm electroporation cuvettes (BioRad, Hercules, CA, USA). To compensate for the amount of cell death induced merely as a consequence of the electroporation procedure, control cells were electroporated in the absence of vector. Electroporation was performed using an EPI 2500 gene pulser (Fischer, Heidelberg, Germany) applying a rectangle pulse of 600 V for 2 ms. After incubating for 15 min at room temperature, the cells were diluted 10-fold with RPMI 1640 (Invitrogen) supplemented with 10% FCS (Integro), 100 IU/ml penicillin, 100 mg/ml streptomycin and 0.125 mg/ml fungizone (Invitrogen) and incubated at 371C and 5% CO 2 . Cell viability was assessed by Annexin V staining determined by flow cytometry using a FACSCalibur (Becton Dickinson). Flow cytometry was also used to determine transfection efficiency of pEGFP-C1 (Invitrogen).
Protein extraction and Western blot analysis
Cell pellets stored at À801C were briefly thawed and resuspended in 50 ml lysis buffer composed of 50 mM Tris buffer, 150 mM NaCl, 100 mM EDTA, 1% Triton X-100, 2 mM PMSF, 3% aprotinine (Sigma), 4 mg/ml pepstatin (Sigma) and 4 mg/ml leupeptin (Sigma). Accordingly, cells were lysed for 15 min on ice. The supernatant of the lysed cells was cleared by centrifugation for 15 min at 13 000 r.p.m. and 41C. The protein content of the cleared lysates was determined using the BCA protein assay (Pierce Biotechnology, Inc., Rockford, USA) with different concentrations of bovine serum albumin as standards.
Cell lysates containing 25 mg of protein were separated on 10% polyacrylamide gels topped with 4% stacking gels, and transferred onto nitrocellulose membranes (Schleichler & Schuell, Dassel, Germany). Western blots were probed with anti-FHIT rabbit polyclonal antibodies (Upstate Biotechnology, Lake Placid, NY, USA) or with anti-Actin mouse monoclonal antibodies (Sigma). Accordingly, the blots were labeled with either peroxidase-conjugated anti-rabbit or anti-mouse IgG antibodies (DAKO, Glostrup, Denmark) and visualized using SuperSignal s West Femto chemiluminescent substrate (Pierce Biotechnology).
Results
FHIT expression in childhood ALL with and without MLL gene rearrangements
More detailed analysis of our recently published microarray study comparing gene expression profiles from MLL rearranged Table 1 ( ALL (MLL) patients (n ¼ 20) to those from patients diagnosed with conventional ALL bearing germ line MLL genes (n ¼ 24)(8), revealed that FHIT expression was significantly (Po0.001) reduced in MLL (Figure 1a ). Using quantitative real-time PCR, we confirmed FHIT mRNA expression to be low in MLL gene rearranged infant ALL (infant MLL) as compared to both infants and older children (non-infants) not carrying chromosomal abnormalities involving the MLL gene (Figure 1b) . Infant MLL patients (n ¼ 35) express B15-fold less (Po0.001) FHIT mRNA compared to infant ALL patients (n ¼ 8) and 11-fold less (Po0.001) than non-infant ALL patients (n ¼ 22) both carrying germ line MLL genes.
FHIT 5 0 CpG island methylation analysis by MSP
Biallelic deletions in FHIT preferentially seem to occur in exon 5, which is the first coding exon of the FHIT gene. 11, 27 Deletions in exon 5 usually result in reduced or aberrant expression of FHIT. The probe sets for FHIT on the Affymetrix microarray chip HG-U95A used in the above-described gene expression profiling study, do not cover exon 5 but are located in more downstream exons. In contrast, the forward primer used in the present quantitative real-time PCR analysis is located within exon 5. Since FHIT mRNA could be detected using this primer, and results similar to the results from the microarray study were obtained, we reasoned that a mechanism other that deletions in exon 5 may underlie reduced FHIT expression in patients with MLL.
Interestingly, all leukemia cell lines with germ line MLL genes tested (HL60, REH, K562, Tom-1, Jurkat, Molt-4 and CCRF-CEM) showed varying levels of FHIT protein expression (although K562 very weakly). In contrast, RS4;11, SEMK2-M1 and MV4-11, all of which harbor translocation t(4;11) involving the MLL gene did not express the FHIT protein (Figure 2 ). However, a smaller protein was detected in the RS4;11 line, which may suggest the presence of truncated (aberrant) FHIT transcripts ( Figure 2) . Nevertheless, no detectable levels of FHIT mRNA were found in these cells, suggesting that this smaller protein band rather is an aspecific protein detected by the polyclonal antibody used in this study, like various other protein bands that are also detected by this antibody, which are not shown in Figure 2 .
A possible explanation for the lack of FHIT protein gene expression in the t(4;11) positive cell lines may be that the FHIT gene is silenced in these cells by 5 0 CpG island hypermethylation. To test this hypothesis we determined the methylation status of FHIT using a methylation-specific PCR (MSP). Since HL60 cells showed substantial expression of the FHIT protein (Figure 2 ), the 5 0 CpG region of FHIT is unlikely to be methylated in these cells. Therefore, DNA extracted from HL60 cells was used as a negative control. As a positive control enzymatically methylated HL60 DNA was used. As shown in Figure 3a , unmethylated FHIT is detected in bisulfite treated HL60 DNA and weakly in enzymaticially methylated DNA. Methylated FHIT is detected in enzymatically methylated DNA only, providing sound controls for both methylated and unmethylated FHIT promoters.
Subsequently, the MSP was used to determine the frequency of FHIT 5 0 CpG island methylation in bisulfite modified DNA from a group of 87 childhood ALL patients consisting of 44 infants and 43 non-infants diagnosed with ALL ( Figure 4) . In 56% (24/43) of the non-infant ALL patients and 93% (41/44) of the infant ALL patients methylated FHIT was observed. The noninfant group was further subdivided into a B-lineage (n ¼ 32) and a T-lineage (n ¼ 11) ALL group, of which 56% (18/32) and 55% (6/11) were positive for methylated FHIT, respectively. The infant ALL group consisted of both of MLL germ line (n ¼ 8) and MLL rearranged (n ¼ 36) patients. The frequency of FHIT methylation in the eight infant MLL germ line cases (63%) resembled that of the non-infant ALL cases, whereas all 36 MLL rearranged cases showed methylated FHIT (Pp0.004). Figure 3b shows FHIT 5 0 CpG methylation in three infant MLL patients bearing the three most common translocations involving MLL, and an infant ALL sample exhibiting germ line MLL, negative for FHIT 5 0 CpG island methylation.
Relation between FHIT 5 0 CpG methylation, FHIT mRNA and FHIT protein expression
The MSP approach only allows the samples to be scored either positive or negative for the presence of methylated 5 0 CpG island sequences. No discrimination can be made in the degree of 5 0 CpG island methylation per sample. Therefore, to establish a relation between positive MSP results and reduced FHIT mRNA expression, we compared FHIT expression levels between noninfant ALL samples displaying methylated and unmethylated FHIT genes, for those patients for which both expression and MSP data was available. Figure 5 shows that unmethylated samples express significantly higher levels of FHIT mRNA as compared to methylated non-infant ALL samples (P ¼ 0.003). 
Re-expression of FHIT upon exposure to 5-aza-2 0 -deoxycytidine (decitabine)
When FHIT is methylated, treatment of the cells with demethylating drugs like, for example 5-aza-2 0 -deoxycytidine (decitabine), should reverse the silencing and result in the reexpression of methylated genes. Figure 7a shows that FHIT protein expression re-emerges in SEMK2-M1 cells after 4 days of exposure to 11 mM of decitabine treatment and successively becomes stronger in the following period of time. Treatment of SEMK2 cells with 1 or 0.5 mM decitabine markedly induced apoptosis (Figure 7b ).
Ectopic FHIT expression in RS4;11 cells
Finally, we studied whether ectopic FHIT expression would confirm tumor suppressor activity in MLL rearranged ALL cells lacking endogenous FHIT expression as a consequence of 5 0 CpG methylation. For this, RS4;11 cells were transfected with the eukaryotic expression vector pSG5 encoding wild-type FHIT or empty vector. Accordingly, the amount of cell death induced (Figure 8b ). The transfection efficiency in RS4;11 cells (viable after electroporation) typically ranges between 40 and 45%. Thus, when corrected for the fact that approximately half of the cells actually were transfected with the pSG5-FHIT vector, the effects of FHIT re-expression in these cells may even be more pronounced.
Discussion
MLL gene rearranged ALL (MLL) represents a unique leukemia predominantly occurring in children less than one year of age (i.e. infants). Infant MLL is an aggressive type of leukemia characterized by exceptionally high white blood cell (WBC) counts at presentation, resistance to multiple chemotherapeutic drugs 3, 5 and a poor treatment outcome. 1,2 Because these patients often relapse on current therapies, a better understanding of this disease is warranted in order to develop more specific and successful treatment strategies. Here we report that infant MLL is characterized by silencing of the putative tumor suppressor gene FHIT as a consequence of 5 0 CpG island hypermethylation in 100% of the cases.
Analysis of our gene expression profiling data revealed FHIT expression to be reduced in patients with MLL when compared to other ALL patients. 8 Recently, a similar observation has been reported. 28 In the present study we confirmed by quantitative real-time PCR that FHIT mRNA expression in infants with MLL is 11-to 15-fold lower as compared to both infant and non-infant ALL patients carrying germ line MLL genes, respectively. We found that the 5 0 CpG island region of FHIT is methylated in all 36 (100%) infant MLL cases tested, whereas in infant and noninfant ALL carrying germ line MLL genes, this frequency was approximately 60%. Recently, Zheng et al. 23 reported hypermethylation of the 5 0 CpG islands region of FHIT to be associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. In their study, the frequency of methylated FHIT was determined in childhood ALL patients positive for translocations t(12;21)/TEL-AML1, or other chromosomal rearrangements (not further specified) as well as in hyperdiploid positive and negative childhood ALL patients. The highest frequencies of methylated FHIT were observed in hyperdiploid positive (B22%) and in B-lineage ALL (B8%) and T-ALL (B38%) patients negative for TEL-AML1 or other translocations. The frequency of FHIT methylation in TEL-AML1 positive patients or patients positive for other translocations both appeared to be o1%. 23 Since translocations involving the MLL gene predominantly occur in infant ALL patients (o1 year of age), and these patients are under-represented in the study of Zheng et al, 23 the remarkably high frequency of FHIT 5 0 CpG methylation in patients harboring MLL rearrangements might therefore have been missed in that study.
The present study further demonstrates that FHIT methylation correlates with strongly reduced FHIT mRNA and FHIT protein expression. Moreover, reduced FHIT expression was confirmed to be a consequence of 5 0 CpG island methylation, as exposing leukemia cells carrying MLL gene rearrangements and methylated (silenced) FHIT to the demethylating drug 5 0 -aza-2 0 -deoxycytidine (decitabine) restores FHIT protein expression. Finally, we demonstrate tumor suppressor activity of FHIT, as restoring the expression of this gene in RS4;11 cells in which FHIT is silenced by hypermethylation led to FHIT expression and induced leukemic cell death. This latter finding supports that the induced cell death as observed in SEMK2 cells upon exposure to decitabine may at least in part be due to restored tumor suppressor activity of FHIT. Obviously, additional genes that become re-expressed upon demethylation may contribute to the observed toxicity to decitabine, especially since it was shown that MLL rearranged ALL cases display a high incidence of silenced genes that are known to be frequently methylated in hematological malignancies. 29 Therefore, treatment with demethylating agents such as decitabine may particularly be effective in MLL rearranged leukemias. Supporting this hypothesis is our finding that decitabine (like other cytosine analogues) depend on the human equilibrative nucleoside transporter 1 (hENT1) to cross the cell membrane (unpublished observations), which is highly expressed in infant MLL cells. 25 Thus, compared to other ALL subtypes, demethylating drugs are likely to upregulate higher numbers of silenced genes and may be transported more effectively into the leukemic cells from (infant) MLL patients.
For childhood leukemia, a two-step mutation model has been proposed in which the first mutation occurs in utero, followed by a second, postnatal mutation giving rise to a clinically overt leukemia. 30 This is, among other evidence, supported by the fact that fusion products generated by balanced translocations involving MLL can be identified on neonatal bloodspots of children developing leukemia within the first years of age. 31 Assuming that rearranged MLL is one of the initial events in the development of infant MLL, the relatively short latency period between this event and the emergence of overt leukemia suggests that possibly all genetic hits necessary for infant MLL to develop occur in utero. FLT3 mutations may be secondary events; 9 however, the incidence of these mutations in infant MLL is limited. 10, 32, 33 Our finding that the FHIT gene is silenced in all infant MLL cases tested, raises important questions; is loss of FHIT expression a secondary genetic hit additionally required for clonal expansion of (pre)neoplastic cells that have acquired translocations involving MLL, or is 5 0 CpG island hypermethylation of FHIT rather a consequence of MLL gene rearrangements? Another possibility might be that methylated FHIT is an epigenetic phenomenon that fits the immunophenotype of highly immature B-cells characteristic for (infant) MLL.
Encompassing a common fragile site, FHIT is highly susceptible to genomic alterations like translocations and deletions upon exposure to environmental carcinogens (e.g. cigarette smoke and alcohol). 34 Interestingly, exposure to cigarette smoke has recently been associated with FHIT methylation in nonmalignant lung tissue from heavy smokers. 26 However, parental smoking during pregnancy does not seem to contribute to the risk of childhood ALL. 35, 36 Therefore, the finding that the frequency of FHIT 5 0 CpG methylation is considerably higher in infant ALL patients carrying translocations involving MLL as compared to MLL germ line infant ALL patients rather implies that FHIT methylation may be driven by the MLL fusion protein itself. This hypothesis is supported by a recent study showing that the leukemia promoting PML-RAR fusion protein in t(15;17) positive acute promyelocytic leukemia (APL) binds to the promoter region of the putative tumor suppressor gene RARb2 and subsequently recruits either DNMT1 or DNMT3 to hypermethylate the promoter. 37 Our finding that 100% of the infant MLL cases tested were positive for FHIT methylation may point to a similar mechanism. Especially since all MLL fusion proteins that arise from fusions between MLL and one of 430 different partner genes 38 have in common that the MLL gene donates its N-terminal region containing the transcription repression domain. Part of this domain is highly homologues to the eukaryotic DNA methyltransferase 1 (DMNT1) and is able to specifically bind to unmethylated CpG sequences, 39 which may be critical in MLLassociated oncogenesis. 40 However, further studies are required to determine whether MLL fusion proteins are indeed responsible for gene silencing.
To conclude, the present study shows that (infant) MLL is uniformly characterized by silencing of the tumor suppressor gene FHIT as a consequence of 5 0 CpG hypermethylation and that restoration of the expression of this gene induces cell death in MLL rearranged ALL cells in vitro. This suggests that silencing of FHIT may be involved in leukemogenesis of this aggressive type of leukemia and may eventually be used as a novel therapeutic target.
